123662-55-5

Basic information

• Product Name: Methanesulfonamide, N-(4-oxo-6-phenoxy-4H-1-benzopyran-7-yl)-
• CAS NO: 123662-55-5
• Molecular Formula: C16H13NO5S
• Molecular Weight: 331.349
• Mol File: 123662-55-5.mol

Chemical Properties

• CAS DataBase Reference: Methanesulfonamide, N-(4-oxo-6-phenoxy-4H-1-benzopyran-7-yl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Methanesulfonamide, N-(4-oxo-6-phenoxy-4H-1-benzopyran-7-yl)-(123662-55-5)
• EPA Substance Registry System: Methanesulfonamide, N-(4-oxo-6-phenoxy-4H-1-benzopyran-7-yl)-(123662-55-5)

Safety Data

• Hazardous Substances Data: 123662-55-5(Hazardous Substances Data)

Upstream product

• 123664-52-8 methyl 2-hydroxy-4-methylsulfonylamino-5-phenoxyphenyl ketone 
• 109-94-4 formic acid ethyl ester 
• 108-95-2 phenol 
• 123664-84-6 N-(5-methoxy-2-phenoxyphenyl)methanesulfonamide 
• 10298-80-3 2-chloro-5-methoxynitrobenzene 
• 76838-72-7 5-methoxy-2-phenoxyaniline 
• 84594-95-6 5-methoxy-1-nitro-2-phenoxybenzene 

Downstream Products

• 123663-49-0 Iguratimod 
• 123663-48-9 N-(3-amino-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl)methanesulfonamide 
• 123664-34-6 3-bromo-2,3-dihydro-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one 
• 123664-21-1 N-(4-oxo-6-phenoxy-2,3-dihydro-4H-7-chromenyl)methanesulfonamide 

Relevant articles and documents

Synthesis and antiinflammatory activity of 7-methanesulfonylamino-6- phenoxychromones. Antiarthritic effect of the 3-formylamino compound (T-614) in chronic inflammatory disease models

A group of derivatives of 7-methanesulfonylamino-6-phenoxychromone (1) at the pyrone and phenoxy rings was synthesized starting with 4-chloro-3- nitroanisole and evaluated against acute and chronic inflammations in oral administration in animals. Significant potency in the rat models of carrageenin-induced edema (CPE) and adjuvant-induced arthritis (AA) was realized with 2'-fluoro and 2',4'-difluoro derivatives (9a and 9d), and 3- formylamino derivative (19a) and its 2'-fluoro and 2',4'-difluoro compounds (22a and 22d), displaying AA therapeutic effect of ED40=2.5-7.1 mg/kg/d for 7 d and AA prophylactic effect of 53-70% inhibition at the dosage of 3 mg/kg/d for 22 d. To identify a candidate for further pharmacological study, the five compounds were subjected to evaluation of their gastro-ulcerogenic liability, leading to selection of the fluorine-free compound 19a which did not cause acute ulceration at 300 mg/kg in oral administration in rats. Compound 19a (ED40=3.6 mg/kg in established AA) possessed good therapeutic efficacy against type II collagen-induced arthritis in DBA/1J mice with doses of 30 and 100 mg/kg, suggesting the development of 19a (designated T-614) as a prospective disease-modifying antirheumatic agent. In addition, a preparative-scale synthetic route to T-614 has been established.

4H-1-benzopyran-4-one derivative or its salt, process for producing the same and pharmaceutical composition comprising the same as active ingredient

This invention relates to a 4H-1-benzopyran-4-one derivative represented by the formula: STR1 or a salt thereof, a process for producing the same and a pharmaceutical composition comprising the same as active ingredient.